Related Experiment Video

Updated: Feb 14, 2026

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

12.1K

Pediatric brain tumors: Update of proteome-based studies

G T Tsangaris1, A K Anagnostopoulos1

  • 1Proteomics Research Unit, Center of Basic Research II, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Journal of Proteomics
|February 23, 2018
PubMed

Insights

Pediatric brain tumors (PBTs) are common childhood cancers. Proteomics and proteogenomics offer new insights into PBTs, aiming for targeted therapies and better treatment monitoring.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Pediatric brain tumors (PBTs) represent a significant oncological challenge in childhood.
  • Current treatments for PBTs can cause severe side effects in developing children.
  • There is a critical need for targeted therapies with reduced toxicity and reliable markers for treatment efficacy assessment.

Purpose of the Study:

  • To review recent advancements in "omics" technologies for pediatric brain tumor research.
  • To highlight the role of proteomics and proteogenomics in understanding PBT pathophysiology.
  • To discuss the potential for developing novel targeted treatments and biomarkers for PBTs.

Main Methods:

  • Review of recent scientific literature on "omics" technologies in PBT research.
  • Focus on protein identification and quantification techniques.
  • Integration of proteomic and genomic data (proteogenomics).

Main Results:

  • "Omics" technologies, particularly proteomics, are rapidly advancing the understanding of PBTs.
  • Proteogenomics offers a powerful approach to investigate the molecular mechanisms underlying PBTs.
  • These advancements are paving the way for more precise and effective therapeutic strategies.

Conclusions:

  • "Omics" approaches, especially proteomics and proteogenomics, are crucial for PBT research.
  • These technologies are essential for identifying novel therapeutic targets and biomarkers.
  • The future of PBT treatment lies in molecularly targeted therapies informed by proteomic and genomic data.

Keywords:
Mass spectrometryMedulloblastomaPediatric brain tumor malignanciesProteinsProteogenomicsProteomicsReview

More Related Videos

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

1.0K
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

11.7K

Related Concept Videos

Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
9.9K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
279
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
247
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
311
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K